Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERASE: Ertugliflozin in ICD/CRT Patients
NCT04600921Phase 3Terminated
- Sponsor
- Medical University of Graz
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and heart failure with mid-range ejection fraction (HFmrEF) comparing Ertugliflozin with Placebo (2 arms). Primary endpoint: Change in Number of Supraventricular Tachycardia (svT)/ Ventricular Fibrillation (VF) Episodes at 52 weeks. Started Jun 2021; status: terminated.
02
Drugs
ertugliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on NCT04600921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04600921.